LOADING
Comparing NVIDIA Corporation (NVDA) and Merck & Company (MRK) across the Technology and Health Care sectors. This side-by-side analysis covers price, valuation multiples, profitability, growth, dividends, and risk metrics to help investors evaluate these two stocks.
| Metric | NVDA | MRK |
|---|---|---|
| Price | $199.75 | $120.41 |
| Change Today | -0.14% | +0.67% |
| Market Cap | $4.85T | $295.4B |
| P/E Ratio | 30.7 | 33.7 |
| Forward P/E | 22.8 | 23.6 |
| PEG Ratio | 0.62 | 5.56 |
| EPS | $6.52 | $3.55 |
| Revenue Growth (YoY) | 85.2% | 4.9% |
| Profit Margin | 63.0% | 13.6% |
| Return on Equity | 114.3% | 18.9% |
| Dividend Yield | 0.02% | 2.84% |
| Beta | 2.20 | 0.22 |
| 52-Week High | $236.26 | $123.33 |
| 52-Week Low | $151.29 | $74.18 |
| Volume | 527K | 44K |
NVIDIA Corporation is the larger company by market capitalization. NVIDIA Corporation trades at a lower P/E ratio, suggesting it may offer better value relative to earnings. Merck & Company offers a higher dividend yield for income investors. NVIDIA Corporation has stronger profit margins. Both stocks should be evaluated in the context of your investment goals, risk tolerance, and portfolio diversification needs.